Xtl Biopharmaceuticals (XTLB) Profit After Tax Growth (5y) (2014 - 2024)
Xtl Biopharmaceuticals (XTLB) Profit After Tax Growth (5y) (2014 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 17.95% |
| Sep 30, 2024 | 35.79% |
| Jun 30, 2024 | 24.42% |
| Mar 31, 2024 | -34.00% |
| Dec 31, 2023 | -26.74% |
| Sep 30, 2023 | -0.45% |
| Jun 30, 2023 | -66.27% |
| Mar 31, 2023 | -24.99% |
| Dec 31, 2022 | -17.55% |
| Sep 30, 2022 | -69.32% |
| Jun 30, 2022 | -15.82% |
| Mar 31, 2022 | 20.27% |
| Dec 31, 2021 | 7.78% |
| Sep 30, 2021 | -36.74% |
| Jun 30, 2021 | -19.24% |
| Mar 31, 2021 | -13.10% |
| Dec 31, 2020 | 29.98% |
| Sep 30, 2020 | -16.39% |
| Jun 30, 2020 | -20.94% |
| Mar 31, 2020 | -14.87% |